BioVersys Advances AlpE TB Candidate Into Phase 2b Trial Within UNITE4TB Platform

BioVersys AG ( (CH:BIOV) ) has shared an update.

BioVersys has dosed the first patient in a Phase 2b clinical trial of alpibectir‑ethionamide (AlpE) for drug‑sensitive pulmonary tuberculosis, conducted within the EU‑backed UNITE4TB platform across six African countries in collaboration with GSK. The study will test a two‑month AlpE plus first‑line regimen followed by standard RH therapy over 18 weeks, with results expected by end‑2027 and a separate Phase 2 trial in TB meningitis planned for the first half of 2026.

The advancement into Phase 2b, supported by generally favorable tolerability data from prior Phase 1 and 2a studies and regulatory orphan‑drug status in both the U.S. and EU, marks a key step in positioning AlpE as a potential new option against drug‑resistant and isoniazid‑resistant TB. Integration into the adaptive UNITE4TB regimen‑selection platform is intended to optimize AlpE’s combination use, reduce the risk of taking suboptimal regimens into Phase 3, and could strengthen BioVersys’ role in the global TB drug‑development ecosystem if the data are positive.

The most recent analyst rating on (CH:BIOV) stock is a Buy with a CHF40.00 price target. To see the full list of analyst forecasts on BioVersys AG stock, see the CH:BIOV Stock Forecast page.

More about BioVersys AG

BioVersys AG (SIX: BIOV) is a clinical-stage biopharmaceutical company developing novel antibacterial therapies for serious, life‑threatening infections caused by multidrug‑resistant bacteria. Its pipeline includes alpibectir‑ethionamide (AlpE), a small‑molecule combination targeting tuberculosis, supported by EU public‑private partnerships and orphan‑drug designations in the U.S. and EU.

Average Trading Volume: 2,950

Technical Sentiment Signal: Strong Sell

Current Market Cap: CHF135.1M

See more data about BIOV stock on TipRanks’ Stock Analysis page.